Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

Julia Scarisbrick(NIHR Surgical Reconstruction and Microbiology Research Centre), Pietro Quaglino(Department of Medical Sciences), Gary S. Wood(Peter MacCallum Cancer Centre), H. Miles Prince(Monash University), Maarten H. Vermeer(Leiden University Medical Center), Sean Whittaker(Guy's Hospital), Y.H. Kim(Stanford University)

British Journal of Dermatology

February 24, 2014

10.1111/bjd.12909

Cited by 150

Related Papers

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

|Blood|2007|1.4k

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

|Journal of Clinical Oncology|2011|657

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

|The Lancet|2019|635

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

|Journal of Clinical Oncology|2001|610

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

|Leukemia|2009|586